Version history

{
  "session_id": "sess_SDA-2026-04-25-gapdebate-afba1a80bd_c747c608",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "codex_cli",
  "action": "synthesize",
  "content": "{\"ranked_hypotheses\":[{\"title\":\"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions\",\"description\":\"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.\",\"target_gene\":\"C1QA,C1QB,C1QC,C1R,C1S,C4A,C4B,C3\",\"dimension_scores\":{\"evidence_strength\":0.74,\"novelty\":0.58,\"feasibility\":0.86,\"therapeutic_potential\":0.88,\"mechanistic_plausibility\":0.79,\"druggability\":0.91,\"safety_profile\":0.62,\"competitive_landscape\":0.63,\"data_availability\":0.77,\"reproducibility\":0.72},\"composite_score\":0.75,\"evidence_for\":[{\"claim\":\"C1q/C3-dependent synaptic pruning is established in development, supporting a pathogenic role for downstream complement activation at synapses.\",\"pmid\":\"18083105\"},{\"claim\":\"Early AD-model synapse loss requires classical complement components and microglial CR3, supporting the idea that downstream cascade activation mediates injury.\",\"pmid\":\"27033548\"},{\"claim\":\"Clinical and translational activity around C1q/classical pathway inhibition indicates tractable target biology and therapeutic interest.\",\"pmid\":\"37246953\"}],\"evidence_against\":[{\"claim\":\"It remains unresolved whether C1q recognition is broadly beneficial in the CNS; some harmful effects may arise from C1q binding itself rather than only downstream protease activation.\",\"pmid\":\"23093673\"},{\"claim\":\"Blocking C1r/C1s may still impair host defense and immune-complex handling, so CNS benefit may not cleanly separate from systemic risk.\",\"pmid\":\"29202623\"}]},{\"title\":\"Microglial TREM2 state determines whether C1q-tagged substrates are cleared adaptively or converted into chronic complement-associated synaptotoxic inflammation\",\"description\":\"This hypothesis reconciles conflicting C1q phenotypes by placing receiver-cell state downstream of a common upstream C1q-tagging event. In a competent TREM2 program, microglia clear tagged material efficiently; in TREM2-impaired states, the same substrates persist, amplifying complement and bystander synapse loss.\",\"target_gene\":\"TREM2,TYROBP,C1QA,C1QB,C1QC,C3\",\"dimension_scores\":{\"evidence_strength\":0.71,\"novelty\":0.68,\"feasibility\":0.72,\"therapeutic_potential\":0.73,\"mechanistic_plausibility\":0.81,\"druggability\":0.62,\"safety_profile\":0.52,\"competitive_landscape\":0.57,\"data_availability\":0.7,\"reproducibility\":0.66},\"composite_score\":0.67,\"evidence_for\":[{\"claim\":\"TREM2 directly interacts with C1q in neurodegeneration-relevant contexts and appears to restrain complement-mediated synapse loss.\",\"pmid\":\"37442133\"},{\"claim\":\"Microglial state is a major determinant of neurodegenerative response programs, making it plausible that identical opsonized substrates can lead to different outcomes.\",\"pmid\":\"40091552\"}],\"evidence_against\":[{\"claim\":\"TREM2 biology is pleiotropic, and observed effects may reflect broader changes in metabolism, clustering, or plaque handling rather than a specific C1q decision node.\",\"pmid\":\"37023079\"},{\"claim\":\"The claim that TREM2 state alone determines adaptive versus toxic handling likely overstates causality because astrocytes, other receptors, and complement regulators also shape outcome.\",\"pmid\":\"37442133\"}]},{\"title\":\"C1q has spatially distinct functions, with synapse-bound C1q primarily nucleating complement-dependent pruning and microglia-associated C1q potentially modulating effector state through receptor-specific signaling\",\"description\":\"The strongest spatial model is a split between substrate marking at synapses and state modulation at microglia. The synaptic arm is well grounded, but the microglial surface-signaling arm remains insufficiently demonstrated in CNS microglia and must be tested under complement-defined conditions that isolate location from ligand identity and microglial state.\",\"target_gene\":\"C1QA,C1QB,C1QC,C4A,C4B,C3,ITGAM,ITGB2,LAIR1\",\"dimension_scores\":{\"evidence_strength\":0.64,\"novelty\":0.76,\"feasibility\":0.69,\"therapeutic_potential\":0.59,\"mechanistic_plausibility\":0.74,\"druggability\":0.41,\"safety_profile\":0.57,\"competitive_landscape\":0.71,\"data_availability\":0.63,\"reproducibility\":0.58},\"composite_score\":0.63,\"evidence_for\":[{\"claim\":\"Synaptic C1q/C3/CR3 pruning is strongly supported in development and disease models, consistent with a location-specific synaptic function.\",\"pmid\":\"18083105\"},{\"claim\":\"Microglial CR3-mediated engulfment downstream of synaptic complement deposition supports a substrate-marking role for synaptic C1q.\",\"pmid\":\"24012419\"},{\"claim\":\"Noncanonical C1q receptor signaling exists in myeloid cells, making a microglial signaling arm biologically plausible.\",\"pmid\":\"23093673\"}],\"evidence_against\":[{\"claim\":\"Direct evidence for a distinct cascade-independent microglial surface-signaling program driven by C1q in resident CNS microglia is limited.\",\"pmid\":\"23093673\"},{\"claim\":\"Apparent location effects may instead arise from unmeasured ligand identity, complement fragment exposure, or pre-existing microglial state.\",\"pmid\":\"27033548\"}]},{\"title\":\"C1q effector output is determined more by binding partner identity than by subcellular location\",\"description\":\"Under this model, C1q is a context decoder whose downstream program depends chiefly on the biochemical identity of the complex it forms, such as neuronal pentraxins, Aβ aggregates, apoptotic membranes, or ECM ligands. Spatial localization remains relevant, but as a secondary variable relative to ligand chemistry and complex composition.\",\"target_gene\":\"C1QA,C1QB,C1QC,NPTX1,NPTX2,APP,C3\",\"dimension_scores\":{\"evidence_strength\":0.58,\"novelty\":0.73,\"feasibility\":0.64,\"therapeutic_potential\":0.54,\"mechanistic_plausibility\":0.77,\"druggability\":0.39,\"safety_profile\":0.56,\"competitive_landscape\":0.69,\"data_availability\":0.61,\"reproducibility\":0.55},\"composite_score\":0.61,\"evidence_for\":[{\"claim\":\"C1q binds diverse ligands including Aβ, indicating that binding-partner identity can shape downstream complement activation.\",\"pmid\":\"8176223\"},{\"claim\":\"Aβ-C1q complexes activate complement in AD-relevant settings, supporting ligand-specific effector programs.\",\"pmid\":\"11714802\"},{\"claim\":\"Neuronal pentraxins interact with C1q, providing a plausible synaptic ligand axis distinct from plaque-associated ligands.\",\"pmid\":\"33628204\"}],\"evidence_against\":[{\"claim\":\"No decisive CNS study yet demonstrates that ligand identity explains more variance than location when ligand, receiver cell, and complement competence are independently controlled.\",\"pmid\":\"33628204\"},{\"claim\":\"Microenvironmental geometry, local complement regulators, and which cell encounters the complex first may rival or exceed ligand identity in determining outcome.\",\"pmid\":\"27033548\"}]},{\"title\":\"APOE isoform modifies the C1q binding landscape, biasing C1q toward inflammatory plaque-associated or synaptotoxic complexes in APOE4 contexts\",\"description\":\"This is best treated as a stratification and response-modifier hypothesis rather than a primary C1q mechanism. APOE4 may alter lipid and aggregate surfaces in ways that shift C1q interactomes toward complement-amplifying complexes, but the causal chain remains loose because ApoE biology is highly pleiotropic.\",\"target_gene\":\"APOE,C1QA,C1QB,C1QC,TREM2,APP\",\"dimension_scores\":{\"evidence_strength\":0.55,\"novelty\":0.67,\"feasibility\":0.67,\"therapeutic_potential\":0.57,\"mechanistic_plausibility\":0.68,\"druggability\":0.48,\"safety_profile\":0.49,\"competitive_landscape\":0.52,\"data_availability\":0.69,\"reproducibility\":0.54},\"composite_score\":0.59,\"evidence_for\":[{\"claim\":\"ApoE can bind C1q in inflammatory contexts, supporting a direct biochemical connection between these pathways.\",\"pmid\":\"30692699\"},{\"claim\":\"APOE genotype strongly shapes AD-relevant plaque and glial biology, making C1q complex remodeling plausible as one downstream consequence.\",\"pmid\":\"30692699\"}],\"evidence_against\":[{\"claim\":\"ApoE effects may operate mainly through lipid trafficking, plaque compaction, or microglial activation upstream of C1q rather than through direct C1q-complex remodeling.\",\"pmid\":\"37023079\"},{\"claim\":\"Isoform-specific synaptic versus plaque partitioning of C1q has not been cleanly established under controlled conditions.\",\"pmid\":\"30692699\"}]},{\"title\":\"C1q shows synapse-class-specific roles, with inhibitory versus excitatory synapses exhibiting different susceptibility to C1q-associated elimination\",\"description\":\"This hypothesis is biologically plausible and potentially important for circuit-level phenotypes, but current support is stronger for contextual selectivity than for distinct intrinsic C1q biochemical programs at inhibitory versus excitatory terminals. It is more valuable for endpoint design and disease-stage interpretation than as a near-term therapeutic thesis.\",\"target_gene\":\"C1QA,C1QB,C1QC,GAD1,GAD2,SLC6A1,SLC17A7,ITGAM,ITGB2\",\"dimension_scores\":{\"evidence_strength\":0.52,\"novelty\":0.64,\"feasibility\":0.6,\"therapeutic_potential\":0.43,\"mechanistic_plausibility\":0.63,\"druggability\":0.24,\"safety_profile\":0.47,\"competitive_landscape\":0.66,\"data_availability\":0.58,\"reproducibility\":0.5},\"composite_score\":0.53,\"evidence_for\":[{\"claim\":\"AD mouse models show cell-type and synapse-class selective engulfment, consistent with possible circuit-biased C1q vulnerability.\",\"pmid\":\"37118504\"},{\"claim\":\"Complement-mediated synapse loss is established, leaving room for differential class susceptibility across circuits.\",\"pmid\":\"27033548\"}],\"evidence_against\":[{\"claim\":\"Observed selectivity may arise from network activity, anatomy, or glial preference rather than synapse-intrinsic C1q coding.\",\"pmid\":\"37118504\"},{\"claim\":\"Evidence does not yet show fundamentally distinct C1q biochemical programs at inhibitory versus excitatory synapses.\",\"pmid\":\"37118504\"}]}],\"knowledge_edges\":[{\"source\":\"C1Q\",\"relation\":\"activates_classical_complement_at\",\"target\":\"vulnerable_synapses\",\"evidence\":\"Supported by developmental and AD-model synaptic pruning literature.\",\"pmid\":\"18083105\"},{\"source\":\"C3_opsonization\",\"relation\":\"promotes_engulfment_via\",\"target\":\"CR3_microglia\",\"evidence\":\"Microglial CR3 is implicated in complement-mediated synapse elimination.\",\"pmid\":\"24012419\"},{\"source\":\"C1Q\",\"relation\":\"binds\",\"target\":\"amyloid_beta\",\"evidence\":\"Direct Aβ-C1q binding supports ligand-dependent complement activation.\",\"pmid\":\"8176223\"},{\"source\":\"C1Q\",\"relation\":\"binds\",\"target\":\"neuronal_pentraxins\",\"evidence\":\"Neuronal pentraxins are candidate synaptic binding partners that may shape C1q function.\",\"pmid\":\"33628204\"},{\"source\":\"TREM2\",\"relation\":\"interacts_with\",\"target\":\"C1Q\",\"evidence\":\"TREM2-C1q interaction links receiver-cell state to complement-associated synapse injury.\",\"pmid\":\"37442133\"},{\"source\":\"APOE\",\"relation\":\"binds_or_modulates\",\"target\":\"C1Q_complexes\",\"evidence\":\"ApoE-C1q interaction suggests genotype-dependent remodeling of inflammatory complexes.\",\"pmid\":\"30692699\"},{\"source\":\"C1R_C1S_inhibition\",\"relation\":\"may_reduce\",\"target\":\"complement_mediated_synapse_loss\",\"evidence\":\"Therapeutic rationale from classical-pathway blockade preserving recognition while limiting amplification.\",\"pmid\":\"37246953\"},{\"source\":\"synapse_class_context\",\"relation\":\"modulates\",\"target\":\"C1Q_associated_vulnerability\",\"evidence\":\"Selective engulfment across synapse classes suggests circuit context affects complement outcomes.\",\"pmid\":\"37118504\"}],\"synthesis_summary\":\"The debate converges on a central conclusion: current evidence does not justify a single-variable answer. C1q biology in neurodegeneration is best explained by the interaction of three partially separable axes: subcellular location, binding-partner identity, and receiver-cell state. The most secure evidence supports a synaptic C1q to C4/C3 to CR3 pruning pathway, while claims about distinct microglial surface-associated C1q signaling remain plausible but underproven in CNS microglia. The cleanest mechanistic next step is a humanized full-factorial system that independently manipulates C1q location, ligand identity, complement activation competence, and microglial state.\\n\\nFor translational prioritization, the leading hypothesis is not that we must fully solve every spatial role of C1q before acting, but that selectively blocking classical-pathway activation downstream of C1q is the most defensible near-term intervention. TREM2 state emerges as the strongest modifier axis, likely determining whether identical C1q-tagged substrates are cleared adaptively or converted into chronic inflammatory injury. Binding-partner and APOE effects are credible stratification layers, while inhibitory-versus-excitatory selectivity is better framed as a circuit-endpoint question than a primary drug thesis. The thrombospondin-rich ECM model is currently too speculative to rank as actionable.\"}",
  "tokens_used": "3263",
  "persona_id": "persona-synthesizer"
}